Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Working Capital Changes (2019 - 2025)

aTYR PHARMA's Other Working Capital Changes history spans 7 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 117.61% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached -$7.3 million, down 230.08%, while the annual FY2025 figure was -$7.3 million, 230.08% down from the prior year.
  • Other Working Capital Changes reached -$1.1 million in Q4 2025 per ATYR's latest filing, up from -$4.8 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $7.6 million in Q1 2024 to a low of -$8.0 million in Q2 2024.
  • Average Other Working Capital Changes over 5 years is $75900.0, with a median of -$180000.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: surged 1624.43% in 2024, then plummeted 2973.72% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $4.0 million in 2021, then plummeted by 185.07% to -$3.4 million in 2022, then soared by 160.49% to $2.1 million in 2023, then skyrocketed by 200.92% to $6.2 million in 2024, then crashed by 117.61% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Other Working Capital Changes are -$1.1 million (Q4 2025), -$4.8 million (Q3 2025), and $714000.0 (Q2 2025).